ERBB2 and breast carcinoma: To understand the functional implications of GATA3 mutations, the National Cancer Institute's tissue-based Clinical Proteomic Tumor Analysis Consortium (CPTAC) database was interrogated for HR +/HER2− breast cancers harboring GATA3 mutations, and the expression and phosphorylation of GATA3 and associated proteins were analyzed.